Olivier Elemento, Director of Englander Institute for Precision Medicine at Weill Cornell Medicine, shared a post on LinkedIn by Emily Pomeroy, Events and Marketing Officer at EMBL’s European Bioinformatics Institute, adding:
“Pathology 2.0: From Spatial Biology to Digital Twins
It was a pleasure to speak at the European Bioinformatics Institute (EMBL-EBI) workshop on ‘Spatial profiling data analysis‘. Thank you, Matt Hall, for the invitation. The strong representation from industry led to excellent conversations and many new connections.
In my talk, I outlined our vision for the next generation of pathology, moving far beyond traditional methods.
High-plex imaging: We are applying advanced spatial techniques, like imaging mass cytometry, to simultaneously map dozens of protein markers on a single cancer tissue slide. This gives us an unprecedented view of the intricate tumor microenvironment (TME) and its connection to tumor cells.
AI-driven discovery: Analyzing this complex spatial data requires sophisticated computational tools. By leveraging AI, we can identify cellular neighborhoods and overarching TME patterns. In our work on lymphoma, this approach revealed distinct microenvironment subtypes that predict a patient’s response to chemotherapy. I think this fusion of high-resolution imaging and machine learning will fundamentally change cancer diagnostics.
Digital Twins: The ultimate goal is to use this deep spatial understanding to create predictive simulations of tumors. These ‘digital twins,’ built as agent-based models, allow us to simulate how a specific patient’s tumor might respond to different treatments. I think these models will become an indispensable part of precision medicine, helping to select the best therapeutic strategy in silico.
For anyone interested, my slides are here.”
Quoting Emily Pomeroy’s post:
“A fantastic start to Day 1 of the EMBL-EBI Industry Programme member workshop on ‘Spatial profiling data analysis‘, hosted at Sanofi today. A huge thank you to all our speakers so far, for their insightful talks and contributions to the panel sessions:
- Olivier Elemento, Cornell University
- Aaron Zefrin Fernandis, MSD
- Fei Chen, Broad Institute
- Vladimir Roudko, AstraZeneca
- Ilya Korsunsky, Harvard University
- Kevin Wei, Harvard University
- Ahmet F. Coskun, Georgia Institute of Technology
- Stephanie Hicks, Johns Hopkins University
This afternoon, we are continuing the conversation with:
- Edward Huttlin, Harvard Medical School
- Maximilian Strauss, OmicVision Biosciences
- Faisal Mahmood, Harvard University
EMBL-EBI Industry
Partnerships: Here.”
More posts featuring Olivier Elemento on OncoDaily.
